Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

Supporting evidence

• Evaluation report

• Final appraisal document committee papers (PDF 828 KB)

  Published:

  14 July 2021

• Appraisal consultation committee papers (PDF 2.21 MB)

  Published:

  14 July 2021